GlassScriptPhysician profile
Shannon Sgro
NPI 1396790358
$7,197.88
in general payments reported to CMS, 2019-2025
24 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $1,052 · 2023: $1,702 · 2024: $2,238 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,560.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,427.06 | 2021-2025 | |
| Lilly USA, LLC | $930.31 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $885.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $517.35 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $503.27 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Leo Pharma INC. | $479.58 | 2022-2025 | Adbry |
| Incyte Corporation | $301.36 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $297.46 | 2022-2025 | |
| Galderma Laboratories, L.P. | $246.55 | 2022-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $240.16 | 2023-2025 | Zoryve |
| Revance Therapeutics, INC. | $239.30 | 2024-2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $211.52 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $195.90 | 2021-2024 | Absorica Ld, Winlevi, Ilumya |
| Amgen INC. | $192.30 | 2023-2025 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $165.20 | 2021-2025 | Jublia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $114.45 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.29 | 2022-2023 | Spevigo |
| Organon LLC | $45.47 | 2025 | Vtama |
| Dermavant Sciences, INC. | $38.40 | 2024 | Vtama |
| Botanix Sb INC | $35.95 | 2025 | Sofdra |
| Pfizer INC. | $34.85 | 2024-2025 | |
| Epi Health, LLC | $16.14 | 2021 | |
| Ucb, INC. | $14.21 | 2025 | Bimzelx |
| Biofrontera INC. | $9.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Sgro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.